Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Post by Lotus33on Dec 29, 2017 7:59am
205 Views
Post# 27243654

From this AM's Globe & Mail

From this AM's Globe & MailGentlemen: FYI

A representative for Health Minister Ginette Petitpas Taylor said there are no plans to create such an organization and that a wide breadth of cannabis studies are being properly directed through the country's three research councils.

In response to a call for more independent cannabis research, the CIHR is set to award 10 grants next month of up to $100,000 for year-long independent projects, with the money becoming available March 1, 2018. CIHR has approved $6.8-million in funding for 15 different cannabis projects since the start of last year.

Critics say the new round of studies are likely already too late to collect meaningful data before the summer.

Rebecca Jesseman, senior policy adviser at the government-funded Canadian Centre on Substance Abuse, said her organization has held panels to try to connect researchers from a wide variety of cannabis projects, but there are many players in the field. The arms-length organization, which was criticized last year in a Health Canada review for its reluctance to embrace the harm-reduction approach to illicit substances, is now in the planning stages of formalizing its role as an organizing force for cannabis research, she said.

"There is just so much happening across the board, so the momentum – in terms of everybody trying to move forward – is certainly there," she said.

"We have some ideas in the hopper about how we can go forward in a more formal way but they're still in the planning stage and we're working on the final details."

 

----------------------------------------------------

CANNABIS RESEARCH

There are dozens of continuing cannabis studies researching everything from how parents should talk to their teens about the drug to how our body's internal cannabinoid system functions.

Here is a small sample of some of these projects.

Marijuana legalization: Impact on prevalence and risk behaviours among youth and young adults in Canada

Where University of Waterloo

Study lead David Hammond

$100,000 from the Canadian Institutes of Health Research

The study will examine the extent to which legalization is associated with changes in five primary outcomes, including patterns of use, risk behaviours and the commercial environment.

Mechanisms underlying schizophrenia

Where Ottawa Hospital Research Institute

Study lead Hsiao-Huei Chen

$646,425 from CIHR

Researchers will study mice to see whether they can inhibit an enzyme in the brain that can lead to malfunction in the regulation of dopamine and cause psychosis. That enzyme also impairs the production of one of the body's own cannabis-like compounds, leading to further problematic brain activity.

Cannabis and Brain Maturation: A population-based study

Where Baycrest Centre for Geriatric Care in Toronto

Study lead Tomas Paus

$1.27-million from CIHR

Researchers will study schizophrenia-related genes and cannabis use during adolescence in a group of 1,000 young men and women recruited and assessed as teenagers about 10 years ago. The study involves repeated assessments of their brains, mental health and substance use, and their genes.

Anti-microbial activity of peptides against plant pathogens and food-borne pathogens

Where McGill University

Study lead Suha Jabaji

$25,000 from the Natural Sciences and Engineering Research Council of Canada

Researchers will collaborate with Victoria-based Green Sky Labs to study the potential of anti-microbial peptides as alternatives to pesticides for the control of fungal and bacterial pathogens of medical cannabis.

Sources: CIHR, NSERC



Bullboard Posts